TOPCAT reveals regional differences in spironolactone effectiveness for HFpEF

Adding spironolactone to existing treatments does not significantly reduce the composite primary outcome in patients with HF and preserved ejection fraction (HFpEF), reported the phase 3 TOPCAT study. Topics: Heart Failure (HF)
Source: ESC News and Press - Category: Cardiology Source Type: news